Klebsiella Pneumoniae Morphology and Characteristics

Klebsiella pneumoniae is a Gram-negative, rod-shaped, non-motile bacterium wrapped in a thick polysaccharide capsule that sets it apart from many of its relatives in the Enterobacteriaceae family.¹ That capsule is the single most recognizable feature under the microscope and the single most important factor in the bacterium’s ability to cause disease. But the morphology and characteristics of K. pneumoniae reach well beyond what a stained slide can show, encompassing a layered set of surface structures, iron-scavenging molecules, biofilm-building machinery, and a remarkable talent for acquiring new antibiotic resistance genes from its surroundings.

Cell Shape, Size, and the Capsule

Under magnification, K. pneumoniae cells appear as short, plump rods roughly 0.3–0.6 micrometers wide and 0.6–1.0 micrometers long during their normal vegetative growth phase.¹ They typically arrange singly, in pairs, or in short chains. Unlike many other gut-dwelling bacteria, they do not have flagella and cannot swim. What they do have is one of the thickest capsules found among common clinical bacteria. This capsule is a hydrated layer of polysaccharides that surrounds the outer membrane, and it is visible in India ink preparations as a bright halo around each cell.

The capsule is not just a cosmetic feature. It shields the bacterium from phagocytosis, the process by which immune cells engulf and destroy invaders. When researchers knocked out capsule-production genes in a virulent K. pneumoniae strain and then restored them with capsule genes from different donor strains, the results were dramatic. Capsule types K1 and K2 restored full virulence, killing all infected mice within 48 hours, while capsule types K3 and K23 could not restore virulence at all, and every mouse survived.² The amount of capsule produced did not correlate with virulence. What mattered was the capsule type, the specific sugar chemistry on the surface.² More than 80 capsule types (K-types) have been identified across K. pneumoniae strains, and this diversity has practical consequences for vaccine development and diagnostic testing.

The Outer Envelope and Lipopolysaccharide

Beneath the capsule sits the outer membrane, which contains lipopolysaccharide (LPS), the classic endotoxin of Gram-negative bacteria. LPS has three parts: the lipid portion embedded in the membrane, a core sugar chain, and the outermost O-antigen repeats. The O-antigen varies between strains and plays its own role in immune evasion. The O1 antigen, one of the most common types, interferes with the complement system, part of the body’s innate defenses that punches holes in bacterial membranes. Research has shown that O1-antigen prevents the final step in this hole-punching process by blocking a key protein from assembling into a functional pore on the bacterial surface.³

The O-antigen and capsule work together. When researchers disrupted the enzyme responsible for attaching the O-antigen repeats to the LPS core, the capsule itself was retained less effectively on the cell surface. Atomic force microscopy confirmed a measurable drop in encapsulation. That loss of capsule made the bacteria more vulnerable to killing by human serum and less virulent in a mouse lung infection model.⁴ So the LPS O-antigen is not just a standalone shield; it acts as an anchor helping keep the capsule in place.

Fimbriae and How K. pneumoniae Sticks to Surfaces

K. pneumoniae produces at least two well-characterized types of hair-like surface appendages called fimbriae. Type 1 fimbriae help the bacterium stick to host cells in the urinary tract. Type 3 fimbriae are built from a structural protein called MrkA and carry a separate adhesin protein, MrkD, at their tips. These two types of fimbriae serve different purposes, and their roles depend on what the bacterium is trying to attach to.

On bare plastic, the kind of surface found on freshly inserted medical devices, the MrkA protein alone can get the job done, anchoring bacteria to the abiotic polymer. But once that device sits in the body for a while, host proteins like collagen and extracellular matrix coat its surface. At that point, the MrkD adhesin becomes essential. Bacteria lacking MrkD could not efficiently colonize collagen-coated surfaces or the natural extracellular matrix laid down by human bronchial cells in the lab.⁵ This two-step adhesion strategy helps explain why K. pneumoniae is so effective at colonizing devices like urinary catheters and endotracheal tubes, first gripping the clean plastic, then switching to a protein-binding mode once host material accumulates.

Both fimbrial types contribute to catheter-associated urinary tract infections, one of the most common hospital-acquired infections linked to this organism.⁶

Biofilm Formation

Once fimbriae have attached K. pneumoniae to a surface, the bacterium can build a biofilm, a structured community of cells encased in a self-produced matrix of sugars and proteins. Biofilms are a problem in hospitals because bacteria living inside them are far more tolerant of antibiotics and disinfectants than free-floating cells. K. pneumoniae biofilms form readily on urinary catheters, and the infections they cause are both frequent and costly to manage.⁷

The capsule itself contributes to biofilm architecture. Strains with a thick, mucoid capsule produce colonies that appear wet and glistening on agar plates, and this same mucoid character makes their biofilms particularly stubborn to remove. During early biofilm development, individual cells first attach reversibly, maintaining their typical rod shape and dimensions. As the community matures, cells become embedded in the extracellular matrix and shift into a state that is harder for the immune system or antibiotics to reach.¹

Siderophores and Iron Scavenging

Iron is critical for bacterial growth, but the human body keeps free iron at vanishingly low levels as a deliberate antimicrobial strategy. K. pneumoniae fights back by secreting siderophores, small molecules that bind iron with very high affinity and shuttle it back to the bacterial cell. What makes this organism unusual is the number of siderophores it can produce. K. pneumoniae can make up to four distinct types: enterobactin, a glucosylated form of enterobactin sometimes called salmochelin, aerobactin, and yersiniabactin.⁸ Not every strain makes all four, but having multiple siderophores lets different strains colonize different body sites, since the iron-scavenging challenge varies between, say, the lung and the bloodstream.

Aerobactin production is especially important for distinguishing the more dangerous hypervirulent strains from ordinary clinical strains, a distinction covered below. A strong link exists between iron acquisition and the severity of K. pneumoniae infections, and siderophore production is now one of the biomarkers researchers use to classify the organism’s threat level.

Hypervirulent Versus Classical Strains

Not all K. pneumoniae are created equal. Over the past few decades, researchers have recognized two broad pathotypes. Classical K. pneumoniae (cKp) is the familiar hospital pathogen: it tends to infect patients who are already sick or immunocompromised, and it often carries a heavy load of antibiotic resistance genes. Hypervirulent K. pneumoniae (hvKp) is a more aggressive pathotype that can cause severe, life-threatening infections in otherwise healthy people. Increased capsule production and aerobactin production are established virulence factors specific to hvKp, and the genetic instructions for these traits typically live on a large virulence plasmid.⁹

Clinically, hvKp is the strain behind community-acquired pyogenic liver abscesses, particularly in East and Southeast Asia, though cases are now reported globally. It can also seed metastatic infections, spreading from a primary site to the eyes, brain, or other organs. Telling the two pathotypes apart in a routine microbiology lab is not straightforward. A test called the “string test,” in which a loop is touched to a colony and pulled away to see if a viscous string forms, has been widely used as a quick bedside indicator of hypervirulence. But its accuracy is only about 0.90, meaning it misclassifies roughly one in ten strains.¹⁰

More reliable approaches count specific genetic biomarkers associated with hypervirulence. A biomarker count of five or more can classify a strain as hvKp with about 94% accuracy.¹¹ The worry in the infectious-disease community is convergence: hvKp strains picking up antibiotic resistance, or heavily resistant cKp strains acquiring virulence plasmids. Historically, hvKp strains carried fewer resistance genes than classical ones. Genotypically, hvKp harbor far fewer resistance determinants on average, and their rates of extended-spectrum beta-lactamase production are lower.¹² But convergent strains that are both hypervirulent and multidrug-resistant have been documented, and their emergence is a major surveillance priority.

Antibiotic Resistance Mechanisms

K. pneumoniae is one of the most important reservoirs of antibiotic resistance genes among all Gram-negative bacteria. Several key resistance genes were first discovered in K. pneumoniae before spreading to other pathogens, including the carbapenem-resistance genes KPC, OXA-48, and NDM-1.¹³ The species has a wider ecological distribution, more varied DNA composition, and a higher burden of mobile genetic elements than many comparable opportunistic bacteria, making it an exceptionally effective trafficker of resistance between environmental microbes and clinical pathogens.

The resistance mechanisms themselves fall into a few categories:

Beta-lactamases: Enzymes that break apart the beta-lactam ring found in penicillins, cephalosporins, and carbapenems. Extended-spectrum beta-lactamases (ESBLs), often encoded on plasmids, can hydrolyze a wide range of these drugs.¹⁴
Carbapenemases: A particularly dangerous subset of beta-lactamases that can destroy carbapenems, the drugs often considered last-line therapy. Some clinical isolates now carry more than one type simultaneously, such as KPC-2 and NDM-5 together on separate plasmids.¹⁵
Porin mutations: Alterations in the channels that allow antibiotics into the cell. Mutations in porins like OmpK37 reduce drug entry, compounding the effect of beta-lactamases.¹⁵
Efflux pumps: Protein machines that actively pump antibiotics out of the cell before they can do damage. Mutations in the regulatory gene AcrR can ramp up efflux activity.

What makes K. pneumoniae especially dangerous from a public-health perspective is how efficiently it shares these resistance tools. Plasmids, which are small circles of DNA that can transfer between bacterial cells, are the main vehicle. In one study of children in Tanzania, a single ESBL-carrying plasmid with a highly conserved backbone was found in 70% of K. pneumoniae isolates across 48 different genetic lineages, carried by both hospitalized and healthy children.¹⁶ Plasmids belonging to the IncF family have been identified as mediators of both within-lineage and between-lineage spread of the widely disseminated ESBL gene blaCTX-M-15.¹⁷ In other words, K. pneumoniae does not just become resistant itself; it acts as a conduit, passing resistance genes onward to other species.

The Klebsiella pneumoniae Species Complex

What clinical labs report as “Klebsiella pneumoniae” is often not a single species but a complex of closely related organisms that look virtually identical under standard laboratory testing. The K. pneumoniae species complex includes at least seven members, among them K. quasipneumoniae and K. variicola, which can cause infections of their own but may differ in virulence and drug-resistance profiles.¹⁸ Standard biochemical tests and automated identification systems in hospitals routinely lump them together, and more accurate differentiation typically requires molecular methods like whole-genome sequencing, which is not available everywhere.

Newer approaches are closing this gap. MALDI-TOF mass spectrometry, already a workhorse in many clinical microbiology labs, can distinguish K. pneumoniae complex members when paired with updated reference libraries. Sensitivity and specificity for separating the main phylogroups range between 80–100% and 97–100%, respectively.¹⁹ Machine-learning models trained on MALDI-TOF data can also predict antibiotic susceptibility patterns, potentially cutting resistance-detection time to one or two hours.²⁰ Getting the species-level identification right matters because different members of the complex may carry different virulence and resistance repertoires, and treating them identically could lead to suboptimal antibiotic choices.

Where K. pneumoniae Lives Outside of Infections

K. pneumoniae is not exclusively a hospital pathogen. It is widely distributed in the environment and can be found in water, soil, and animals.²¹ It can also colonize the human gut without causing any symptoms. This asymptomatic gastrointestinal carriage is increasingly recognized as a reservoir for infections. In many cases, the strain that eventually causes a bloodstream infection or pneumonia in a hospitalized patient is the same strain that was already quietly living in that person’s intestines. Gut colonization also allows host-to-host transmission through the fecal-oral route.²²

The capsule and biofilm-forming ability that make K. pneumoniae so resilient in infections also help it survive on inanimate surfaces in healthcare settings. Medical equipment, bed rails, and sinks can harbor the organism for extended periods, providing opportunities for it to reach vulnerable patients. This environmental persistence is one reason why infection-control measures in hospitals pay so much attention to surface decontamination and hand hygiene.

Immune Evasion Beyond the Capsule

The capsule is the most studied immune-evasion tool, but K. pneumoniae uses multiple strategies in concert. The capsule reduces phagocytosis by macrophages in the lung. When researchers used a mutant strain with a defective capsule, alveolar macrophages ingested those cells at substantially higher rates than the wild-type, encapsulated strain, and the fraction of macrophages that contained bacteria was significantly greater.²³ Meanwhile, the O-antigen blocks complement-mediated killing as described earlier, and the overall package of capsule, LPS, fimbriae, and siderophores has been described as the four main pillars of virulence across different infection models.²⁴

The interplay matters. The capsule blocks phagocytosis but can also mask fimbriae, potentially reducing adhesion. The bacterium appears to modulate capsule expression depending on context, producing less of it when it needs to stick to a surface and more when it needs to evade immune cells. This trade-off helps explain the somewhat counterintuitive finding that loss of O-antigen, which leads to reduced capsule retention, actually increases biofilm formation.⁴ Less capsule means fimbriae are more exposed, which means better adhesion and more biofilm.

Phage-Based Approaches to Capsule Destruction

The capsule’s centrality to K. pneumoniae virulence has made it an appealing therapeutic target. Bacteriophages, viruses that infect bacteria, have co-evolved with K. pneumoniae and often carry enzymes called capsular depolymerases that break down specific capsule types. These enzymes essentially strip the bacterium of its armor, leaving it vulnerable to the host immune system and potentially to antibiotics that the biofilm or capsule previously blocked.

Researchers studying one such enzyme, KP34gp57 from a Klebsiella phage, solved its crystal structure and discovered that the enzyme can remain active even after being trimmed down to a smaller, monomeric form. These “mini-enzymes” were stable and fully functional at degrading capsule.²⁵ The challenge is capsule-type specificity: most depolymerases recognize only one or a few K-types, so a cocktail of enzymes or phages would be needed to cover the diversity found in clinical settings. Still, as antibiotic resistance narrows the available treatment options, phage-derived enzymes are among the more promising alternatives being explored.

Range of Infections

K. pneumoniae causes a broad spectrum of infections. Pneumonia, especially in hospitalized patients on ventilators, is the most historically well-known, but urinary tract infections, bloodstream infections, wound infections, and liver abscesses all belong to its repertoire.²⁴ The organism can colonize mucosal surfaces and then spread from those sites to deeper tissues, turning a harmless colonizer into a potentially fatal pathogen once the right opportunity arises, such as a weakened immune system, a surgical wound, or an indwelling medical device.²¹

The community-acquired liver abscess syndrome, driven primarily by hvKp strains carrying K1 or K2 capsules, stands out because it strikes people with no obvious immune deficiency. It was first described in Taiwan in the 1980s and has since spread globally. These abscesses can seed secondary infections in the eyes, central nervous system, and lungs. For clinicians, recognizing whether a K. pneumoniae isolate belongs to the hypervirulent pathotype is increasingly important for making decisions about the intensity and duration of treatment, and for counseling patients about the risk of metastatic complications.

1
Veterinary World. Morphological and adhesive properties of Klebsiella pneumoniae biofilms
2
PubMed Central. Capsule type defines the capability of Klebsiella pneumoniae in evading Kupffer cell capture in the liver
3
Scientific Reports. Klebsiella LPS O1-antigen prevents complement-mediated killing by inhibiting C9 polymerization
4
PubMed Central. LPS O Antigen Plays a Key Role in Klebsiella pneumoniae Capsule Retention
5
PubMed. Klebsiella pneumoniae MrkD-mediated biofilm formation on extracellular matrix- and collagen-coated surfaces
6
PubMed Central. Role of Klebsiella pneumoniae type 1 and type 3 fimbriae in colonizing silicone tubes implanted into the bladders of mice as a model of catheter-associated urinary tract infections
7
PubMed Central. The In Vitro Ability of Klebsiella pneumoniae to Form Biofilm and the Potential of Various Compounds to Eradicate It from Urinary Catheters
8
PubMed Central. Siderophore-mediated iron acquisition by Klebsiella pneumoniae
9
PubMed Central. Hypervirulent Klebsiella pneumoniae
10
PubMed Central. Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae
11
PubMed Central. Differentiation of hypervirulent and classical Klebsiella pneumoniae with acquired drug resistance
12
Nature Communications Medicine. Revisiting definitions of hypervirulent and classical Klebsiella pneumoniae through virulence factors and disease phenotype
13
PubMed. Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria
14
PubMed Central. Mechanisms of Antimicrobial Resistance in Klebsiella: Advances in Detection Methods and Clinical Implications
15
PubMed Central. Co-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant Klebsiella Pneumoniae Clinical Isolate: Genetic Insights and Risks
16
PubMed Central. Horizontal Plasmid Transfer among Klebsiella pneumoniae Isolates Is the Key Factor for Dissemination of Extended-Spectrum β-Lactamases among Children in Tanzania
17
Nature Communications. Clonal background and routes of plasmid transmission underlie antimicrobial resistance features of bloodstream Klebsiella pneumoniae
18
PubMed. PCR system for the correct differentiation of the main bacterial species of the Klebsiella pneumoniae complex
19
PubMed Central. Identification of Klebsiella pneumoniae, Klebsiella quasipneumoniae, Klebsiella variicola and Related Phylogroups by MALDI-TOF Mass Spectrometry
20
PubMed. Machine learning powered profiling: Rapid identification of Klebsiella Pneumoniae drug resistance from MALDI-TOF MS
21
PubMed Central. General Overview of Klebsiella pneumonia: Epidemiology and the Role of Siderophores in Its Pathogenicity
22
PubMed Central. Deciphering the gastrointestinal carriage of Klebsiella pneumoniae
23
PLOS ONE. Role of Bacterial Surface Structures on the Interaction of Klebsiella pneumoniae with Phagocytes
24
PubMed Central. Klebsiella pneumoniae: Going on the Offense with a Strong Defense
25
PubMed Central. Klebsiella phage KP34gp57 capsular depolymerase structure and function: from a serendipitous finding to the design of active mini-enzymes against K. pneumoniae